Gilead Sciences’ (GILD) new CEO Daniel O’Day is an A-list pharma veteran, one of the industry’s most successful marketers of cancer drugs, and a decent dealmaker — three qualities the struggling biotech needs to start growing again.

O’Day, the longtime Roche executive most recently in charge of its pharmaceuticals group, was named Gilead’s new CEO on Monday, the company announced. He will start on March 1, 2019, and replace John Milligan, who is leaving at the end of the year after announcing his retirement in July. O’Day’s new job was reported first by the Wall Street Journal on Sunday night.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy